Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05601752 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3)

StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv11
  2. Lead sponsor: Adaptimmune to USWM CT, LLCv10
  3. Trial status: Recruiting to Active, Not Recruiting Study sites: 28 to 23v9 Show 1 more changeShow less
    • Study sites: 28 to 23
  4. Primary and study completion dates: Oct 25, 2025 to Aug 12, 2026 Study sites: 29 to 28 · Eligibility criteria expanded, about 519 words · Secondary endpoints: details revised at 10 of 12 entriesv8 Show 3 more changesShow less
    • Study sites: 29 to 28
    • Eligibility criteria expanded, about 519 words
    • Secondary endpoints: details revised at 10 of 12 entries

    See this version in full on ClinicalTrials.gov ↗

  5. Study sites: 31 to 29v7
Show 5 earlier versionsHide 5 earlier versions
  1. Site details revised at 2 of 31 sitesv6
  2. Site details revised at 1 of 31 sitesv5
  3. Study sites: 30 to 31v4
  4. Trial status: Not Yet Recruiting to Recruiting Start date changed from estimate of Mar 1, 2023 to Jun 26, 2023v3 Show 1 more changeShow less
    • Start date changed from estimate of Mar 1, 2023 to Jun 26, 2023
  5. Start date: Dec 4, 2022 to Mar 1, 2023v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a phase 2, open-label, randomized, non-comparative clinical trial to evaluate the clinical outcome of ADP A2M4CD8 as monotherapy and in combination treatment with nivolumab in human leukocyte antigen (HLA) A2+ subjects with recurrent ovarian cancer positive for MAGE-A4.
Trial Details
NCT Number NCT05601752
Lead Sponsor USWM CT, LLC
Collaborators: GOG Foundation
Conditions Ovarian Cancer
Enrollment 66 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov